Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 27, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Langerhans cell histiocytosis.

Joan Manel Gasent Blesa1, Vicente Alberola Candel, Carlos Solano Vercet

  • 1Hospital General Universitari Marina Alta, Dènia, Alacant, Spain. joanmagasent@telefonica.net

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|November 19, 2008
PubMed
Summary

Langerhans cell histiocytosis (LCH) is a rare proliferative disorder with uncertain origins. This review covers LCH aspects, treatments, and presents an adult case study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educational Interventions for the Timely Diagnosis of Pediatric Patients With Cancer: A Scoping Review.

JCO global oncology·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026
Same author

Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across Europe.

JCO global oncology·2026
Same author

Ethnic and Socioeconomic Factors Associated with Locally Advanced Retinoblastoma: A Retrospective Study.

Ocular oncology and pathology·2026
Same author

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Blood advances·2026
Same author

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Blood advances·2026

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Langerhans cell histiocytosis (LCH) is a poorly understood proliferative disease.
  • Current classification is based on systems involved and organ dysfunction.
  • The etiology is uncertain, with some cases suggesting a reactive condition.

Purpose of the Study:

  • To present a comprehensive literature review of Langerhans cell histiocytosis.
  • To discuss various treatment approaches and existing protocols.
  • To report on an adult clinical case of LCH.

Main Methods:

  • Literature review of all aspects of LCH.
  • Analysis of different therapeutic approaches.
  • Presentation of an adult clinical case.

Related Experiment Videos

Last Updated: Jun 27, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Main Results:

  • LCH etiology remains uncertain, with potential reactive components.
  • Cytokines are implicated in LCH pathogenesis.
  • Long-term organ dysfunction may necessitate ongoing supportive care.

Conclusions:

  • LCH requires diverse therapeutic strategies based on organ involvement.
  • Despite treatment, long-term organ dysfunction is a significant concern.
  • Further research into LCH etiology and optimal management is warranted.